Human Genome Sciences (HGSI) Gets FDA Okay for Phase 3 LymphoStat-B Study
Human Genome Sciences, Inc. (Nasdaq: HGSI) received a Special Protocol Assessment from the FDA, agreeing to the Company's Phase 3 clinical development program for LymphoStat-B in patients with active systemic lupus erythematosus.
CEO Thomas Watkins said, "We expect to initiate Phase 3 trials of LymphoStat-B before the end of 2006, and we look forward to moving ahead with site activation and patient enrollment."
Related Categories
FDAStocks Mentioned
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
